Show
Sort by
-
Cost analysis: treatment of chemotherapy-induced anaemia with erythropoiesis-stimulating agents (ESAS) in Spain
-
Cost analysis of anemia treatment with erythropoiesis-stimulating agents (ESAS) in cancer patients receiving chemotherapy in Italy
-
Cost analysis of anemia treatment with erythropoieses-stimulating agents (ESAS) in cancer patients receiving chemotherapy: a multicountry approach
-
Belgian budget impact analyses of aliskiren (Tekturna/Rasilez) in hypertension
-
Cost-effeciveness of Fentanyl its (ionsys(TM)) in post-operative pain management: a finnish hospital perspective analysis
-
Position paper of the Belgian Working Group on Cardiovascular Prevention and Rehabilitation: cardiovascular rehabilitation
-
Cost-consequence analysis of darbepoetin alfa administered every 3 weeks (Q3W_DA) compared to weekly epoetin alfa (QW_EA) or epoetin beta (QW_EB) in patients with chemotherapy-induced anemia (CIA): The Italian case
-
Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases
-
A health economic evaluation of concomitant surgical ablation for atrial fibrillation
-
A cost-consequence analysis of darbepoetin alfa administered every 3 weeks (Q3W_DA) compared to weekly epoetin alfa (QW_EA) or epoetin beta (QW_EB) in patients with chemotherapy-induced anemia (CIA): The German case